Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.
528 patients around the world
Available in Argentina, United States
Amgen
20Research sites
528Patients around the world
This study is for people with
Esophageal cancer
Gastric cancer
Gastroesophageal cancer
Requirements for the patient
To 100 Years
All Gender
Medical requirements
Sites
Centro de Investigaciones Clínicas - Clínica Viedma - Río Negro